Stockscreener 앱 받기
6.48
5.48%
-0.27
시간 외 거래:
6.45
-0.03
-0.46%
전일 마감가:
$6.75
열려 있는:
$6.87
하루 거래량:
358.58K
Relative Volume:
1.68
시가총액:
$188.63M
수익:
$1.78M
순이익/손실:
$-151.77M
주가수익비율:
-1.1176
EPS:
-5.7981
순현금흐름:
$-79.40M
1주 성능:
+4.76%
1개월 성능:
-5.48%
6개월 성능:
-16.05%
1년 성능:
-30.35%
1일 변동 폭
$6.04
$7.37
1주일 범위
$6.04
$7.37
52주 변동 폭
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.42 | 198.33M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com Canada
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com
Cartesian Secures Major Loan Facility to Extend Runway - TipRanks
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times
Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView
Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union
Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan
Up to $150M backs CAR-T for myasthenia gravis, data in 2027 - Stock Titan
Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Soft Quarter Raises QuestionsCollaborative Trading Signals - Newser
Cartesian Therapeutics (RNAC) Drops -7.33% — Key Support at $6.07 2026-05-19Investment Signal Network - newser.com
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Q2 EPS Estimate for Cartesian Therapeutics Cut by Analyst - MarketBeat
TradingKey - TradingKey
RNAC Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Cartesian Therapeutics stock price target lowered to $25 by H.C. Wainwright on launch timing - Investing.com Canada
Cartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - Quiver Quantitative
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Number of shareholders of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cell therapy advances for myasthenia gravis presented by Cartesian Therapeutics at major conference - Traders Union
RNAC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TD Cowen Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating - Moomoo
Insider Sales At Cartesian Therapeutics Landed A Good Price - Moomoo
CARTESIAN THERAPEUTICS, INC. (RNAC) - MSN
FMR LLC (RNAC) holds 799,743 shares, 3.0% stake — Amendment No. 4 - Stock Titan
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Five new Cartesian hires get stock options priced at $6.22 - Stock Titan
The labor dynamics in Cartesian Therapeutics (RNAC) results | Cartesian Therapeutics Posts Steep 62% EPS MissExpert Market Insights - newser.com
Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates - MSN
RNAC Reiterated by Cartesian Therapeutics -- Price Target Mainta - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Reports Q1 2026 Financial Results and Advances Descartes-08 Clinical Trials in Autoimmune Diseases - Minichart
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Risks, and Financial Results - Minichart
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cartesian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Myasthenia Gravis Market: Fast-Growing Therapeutics Outlook by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cartesian Therapeutics posts first quarter 2026 financial results and issues business update - Traders Union
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
8-K: Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.49%
0.12%
자본화:
|
볼륨(24시간):